Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Kristin Rathje, Kordelia Barbullushi, Nico Gagelmann, Anita Badbaran, Johanna Richter, Mathias Schäfersküpper, Franziska Elisabeth Marquard, Radwan Massoud, Sofia Oechsler, Evgeny Klyuchnikov, Ina Rudolph, Silke Heidenreich, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2024-207569

Published: 2024

Journal Articles

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Radwan Massoud, Margherita Ursi, Francesco Barbato, Francesco De Felice, Enrico Maffini, Marcello Roberto, Evgeny Klyuchnikov, Claudia Langebrake, Nico Gagelmann, Gabriele Zeck, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger, Francesca Bonifazi

Blood (2024) 144 (Supplement 1): 7374.

https://doi.org/10.1182/blood-2024-211102

Published: 2024

Journal Articles

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Normann Steiner, Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Gabriele Zeck, David Nachbaur, Dominik Wolf, Nico Gagelmann, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2024-205849

Published: 2024

Journal Articles

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Nico Gagelmann, Marie Quarder, Anita Badbaran, Christine Wolschke, Kristin Rathje, Mathias Schäfersküpper, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Radwan Massoud, Johanna Richter, Dietlinde Janson, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 630.

https://doi.org/10.1182/blood-2023-191242

Published: 2023

Journal Articles

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis A. Ayuk, Ulrike Bacher, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2023-188998

Published: 2023

Journal Articles

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Radwan Massoud, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Anita Badbaran, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 7014.

https://doi.org/10.1182/blood-2023-188880

Published: 2023

Journal Articles

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Radwan Massoud, Evgeny Klyuchnikov, Ameya Shrinivas Kunte, Christian Niederwieser, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kröger

Blood (2023) 142 (Supplement 1): 2156.

https://doi.org/10.1182/blood-2023-188745

Published: 2023

Journal Articles

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Christine Wolschke, Raissa Adjallé, Dietlinde Janson, Carolina Berger, Evgeny Klyuchnikov, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 7672–7673.

https://doi.org/10.1182/blood-2022-170107

Published: 2022

Journal Articles

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Ameya Shrinivas Kunte, Nico Gagelmann, Anita Badbaran, Carolina Berger, Radwan Massoud, Evgeny Klyuchnikov, Christine Wolschke, Dietlinde Janson, Ulrike Fritsche-Friedland, Boris Fehse, Nicolaus Kroeger, Francis A. Ayuk

Blood (2022) 140 (Supplement 1): 7531–7532.

https://doi.org/10.1182/blood-2022-168667

Published: 2022

Journal Articles

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatjana Zabelina, Wolschke Christine, Francis Ayuketang Ayuk, Ulrike Fritsche-Friedland, Axel R. Zander, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 3897.

https://doi.org/10.1182/blood-2021-153157

Published: 2021

Journal Articles

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Maximilian Christopeit, Dietlinde Janson, Francis A. Ayuk, Christine Wolschke, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2021-152148

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation As Salvage Therapy for First Relapse after Autografting in Multiple Myeloma Patients

Evgeny Klyuchnikov, MD, Christine Wolschke, MD, Anita Badbaran, Maximilian Christopeit, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Nicolaus Kröger, MD

Blood (2016) 128 (22): 4619.

https://doi.org/10.1182/blood.V128.22.4619.4619

Published: 2016

Journal Articles

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Evgeny Klyuchnikov, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Maximilian Christopeit, MD, Raissa Adjalle, MD, Andre van Randenborgh, MD, Christine Wolschke, MD, Nicolaus Kröger

Blood (2016) 128 (22): 3437.

https://doi.org/10.1182/blood.V128.22.3437.3437

Published: 2016

Journal Articles

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Blood (2016) 127 (7): 938–947.

https://doi.org/10.1182/blood-2015-09-671834

Published: 2016

Includes: Supplemental data

Journal Articles

Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Blood (2015) 126 (23): 1958.

https://doi.org/10.1182/blood.V126.23.1958.1958

Published: 2015

Journal Articles

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Nicolaus Kröger, Tatjana Zabelina, Francis Ayuk, Haefaa Alchalby, MD, Christine Wolschke, Thomas Stübig, Evgeny Klyuchnikov, Jürgen Berger, Axel R. Zander, MD

Blood (2012) 120 (21): 3055.

https://doi.org/10.1182/blood.V120.21.3055.3055

Published: 2012

Journal Articles

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Blood (2012) 120 (20): 4256–4262.

https://doi.org/10.1182/blood-2012-06-436725

Published: 2012

Includes: Supplemental data

Journal Articles

Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Maximilian Christopeit, MD, Karolin Miersch, Evgeny Klyuchnikov, MD, Mascha Binder, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, Philippe Schafhausen, MD, Carsten Bokemeyer, M.D., Torsten Haferlach, MD, Nicolaus Kroeger, MD, Ulrike Bacher, MD

Blood (2011) 118 (21): 4467.

https://doi.org/10.1182/blood.V118.21.4467.4467

Published: 2011

Journal Articles

Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)

Ulrike Bacher, MD, Evgeny Klyuchnikov, MD, Jeanette Carreras, MPH, Jennifer Le-Rademacher, PhD, Ginna G. Laport, MD, Silvia Montoto, MD, David G. Maloney, MD, PhD, Parameswaran Hari, MBBS, MD, MRCP

Blood (2011) 118 (21): 501.

https://doi.org/10.1182/blood.V118.21.501.501

Published: 2011

Journal Articles

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Nicolaus Kröger, Evgeny Klyuchnikov, MD, Thomas Stübig, MD, Christine Wolschke, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, York Hildebrandt, Ulrike Bacher, MD, Anita Badbaran, Georgia Schilling, MD, Orhan Sezer, MD, PhD, Djordje Atanackovic, M.D., Martin Kropff, MD, Axel R. Zander, MD

Blood (2011) 118 (21): 3024.

https://doi.org/10.1182/blood.V118.21.3024.3024

Published: 2011

NARROW

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

The Impact of Anti-T-Lymphocyte-Globulin Dosing on Gvhd in Matched Sibling Allogeneic Stemcell Transplantation

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Allogeneic Stem Cell Transplantation As Salvage Therapy for First Relapse after Autografting in Multiple Myeloma Patients

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors

Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT

Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Bone Marrow Cellularity, but Not Dysplasia, Is An Additional Prognostic Factor for Patients with Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL)

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only